ArticleExperimental & molecular medicine2018
Protectin DX increases alveolar fluid clearance in rats with lipopolysaccharide-induced acute lung injury.
Article in Experimental & molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Glycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections.Bioactive materials · 2026Article
- 10-epi-Protectin DX and Resolvin D5International journal of molecular sciences · 2026Article
- FGF21 promotes the resolution of inflammation through the ALOX15/SPM pathway in acute respiratory distress syndrome.Respiratory research · 2026Article
- The Effects of the Natriuretic Peptide System on Alveolar Epithelium in Heart Failure.International journal of molecular sciences · 2025Article
- The potential of exogenous specialized pro-resolving mediators in protecting against sepsis-associated lung injury: a review.Frontiers in pharmacology · 2025Review
- Article
- Relationship between blood urea nitrogen and 28-day all-cause mortality in patients with acute pulmonary edema: a retrospective analysis of the MIMIC-IV database.Frontiers in cardiovascular medicine · 2025Article
- Review
- CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation.Circulation research · 2024Article
- The potential role of n-3 fatty acids and their lipid mediators on asthmatic airway inflammation.Frontiers in immunology · 2024Review
- Protectin DX as a therapeutic strategy against frailty in mice.GeroScience · 2023Article
- Hypoxia modeling techniques: A review.Heliyon · 2023Review
- Protectin DX Relieve Hyperoxia-induced Lung Injury by Protecting Pulmonary Endothelial Glycocalyx.Journal of inflammation research · 2023Article
- COVID-19 and cancer: start the resolution!Cancer metastasis reviews · 2022Review
- Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGDInternational immunopharmacology · 2022Article
- The Protective Effect of Artesunate on LPS-Induced Acute Respiratory Distress Syndrome through Inhibiting NLRP3 Inflammasome Signaling.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Screening of Phospholipids in Plasma of Large-Artery Atherosclerotic and Cardioembolic Stroke Patients With Hydrophilic Interaction Chromatography-Mass Spectrometry.Frontiers in molecular biosciences · 2022Article
- Effects of maoto (ma-huang-tang) on host lipid mediator and transcriptome signature in influenza virus infection.Scientific reports · 2021Article
- Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential.Frontiers in pharmacology · 2021Review
- Assessing the safety of transarterial locoregional delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat liver.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome is a life-threatening critical syndrome resulting largely from the accumulation of and the inability to clear pulmonary edema. Protectin DX, an endogenously produced lipid mediator, is believed to exert anti-inflammatory and pro-resolution effects. Protectin DX (5 µg/kg) was injected i.v. 8 h after LPS (14 mg/kg) administration, and alveolar fluid clearance was measured in live rats (n = 8). In primary rat ATII epithelial cells, protectin DX (3.605 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.